“Clinical development strategies are beginning to include RWE for measuring expected safety and effectiveness background rates and providing context for interpreting the results of single-arm ...

“Against this background, the company has announced that it will buy back shares.” RWE has faced growing investor frustration in recent months over its falling share price and its focus on US ...